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Progressive encephalopathy with oedema, hypsarrhythmia, and optic atrophy (PEHO) syndrome is an early childhood onset, severe
autosomal recessive encephalopathy characterized by extreme cerebellar atrophy due to almost total granule neuron loss. By
combining homozygosity mapping in Finnish families with Sanger sequencing of positional candidate genes and with exome
sequencing a homozygous missense substitution of leucine for serine at codon 31 in ZNHIT3 was identiﬁed as the primary
cause of PEHO syndrome. ZNHIT3 encodes a nuclear zinc ﬁnger protein previously implicated in transcriptional regulation
and in small nucleolar ribonucleoprotein particle assembly and thus possibly to pre-ribosomal RNA processing. The identiﬁed
mutation affects a highly conserved amino acid residue in the zinc ﬁnger domain of ZNHIT3. Both knockdown and genome
editing of znhit3 in zebraﬁsh embryos recapitulate the patients’ cerebellar defects, microcephaly and oedema. These phenotypes are
rescued by wild-type, but not mutant human ZNHIT3 mRNA, suggesting that the patient missense substitution causes disease
through a loss-of-function mechanism. Transfection of cell lines with ZNHIT3 expression vectors showed that the PEHO syn-
drome mutant protein is unstable. Immunohistochemical analysis of mouse cerebellar tissue demonstrated ZNHIT3 to be expressed
in proliferating granule cell precursors, in proliferating and post-mitotic granule cells, and in Purkinje cells. Knockdown of Znhit3
in cultured mouse granule neurons and ex vivo cerebellar slices indicate that ZNHIT3 is indispensable for granule neuron survival
and migration, consistent with the zebraﬁsh ﬁndings and patient neuropathology. These results suggest that loss-of-function of a
nuclear regulator protein underlies PEHO syndrome and imply that establishment of its spatiotemporal interaction targets will be
the basis for developing therapeutic approaches and for improved understanding of cerebellar development.
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Introduction
PEHO syndrome (progressive encephalopathy with
oedema, hypsarrhythmia, and optic atrophy; MIM
260565) is a rare disorder with distinctive neuroradiologi-
cal and neuropathological ﬁndings. The diagnostic criteria
include infantile-onset hypotonia, infantile spasms with
hypsarrhythmia, profound psychomotor retardation, optic
atrophy, and progressive brain atrophy primarily involving
the cerebellum and brainstem (Somer, 1993a; Somer et al.,
1993a). Additional clinical ﬁndings include typical facial
dysmorphism (Fig. 1A), oedema of the face and limbs
(Fig. 1B), brisk tendon reﬂexes in early childhood, abnor-
mal brainstem auditory evoked potentials, slowed nerve
conduction velocity in late childhood, and dysmyelination
observed on MRI (Fig. 1C–G) (Salonen et al., 1991; Somer,
1993a; Somer and Sainio, 1993; Somer et al., 1993a,b).
Head circumference is average at birth, but drops to 2
standard deviations during infancy (Somer, 1993a).
Microcephaly at birth, abnormal gyral formation, predom-
inant spasticity in infancy, reappearance of visual contact
after cessation of infantile spasms, hepato- or splenomegaly
and storage disorder in histological studies argue against
diagnosis of PEHO syndrome (Somer, 1993a). There is
cerebral and extreme cerebellar cortical atrophy (Fig. 1H),
with the inner granule cell layer being either totally absent
or containing only few neurons and the Purkinje
cells showing abnormal dendritic arborization and mis-
alignment (Haltia and Somer, 1993). The optic nerves
show loss of myelinated axons and gliosis, while the retinal
nerve ﬁbre and ganglion cell layers are atrophic (Somer
et al., 1993b).
PEHO syndrome is enriched in the Finnish population
with an estimated incidence of 1:74 000 (Somer, 1993a)
and 30 clinically diagnosed patients. PEHO syndrome is
very rare in other populations with 525 reported patients
(Field et al., 2003; Alfadhel et al., 2011; Caraballo et al.,
2011). Patients with PEHO-like features are more common
and present with many but not all characteristic ﬁndings of
PEHO syndrome, e.g. have atypical neuroradiological ﬁnd-
ings or show no sign of progression (Chitty et al., 1996;
Field et al., 2003; Longman et al., 2003). Recessive disease-
causing variants in the SEPSECS gene involved in seleno-
protein biosynthesis have been described in four Finnish
patients with PEHO-like features (Anttonen et al., 2015),
but the cause for autosomal recessive PEHO syndrome has
remained unknown.
Here we report the identiﬁcation of a missense loss-of-
function variant in ZNHIT3 as the primary defect under-
lying PEHO syndrome. Using knockdown and genome
editing experiments in zebraﬁsh embryos and knockdown
experiments in mouse cerebellar neurons, we show that
ZNHIT3 is essential for normal cerebellar development.
Materials and methods
Study subjects
The study included 23 Finnish patients with a clinical diagno-
sis of PEHO and 40 Finnish and 47 non-Finnish patients with
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PEHO-like features. In addition, clinical information was
available from three patients with a clinical diagnosis of
PEHO but DNA sample available only from parents. The
study was approved by an Institutional Review Board at the
Helsinki University Hospital and written informed consent was
obtained from all study subjects or their legal guardians ac-
cording to the Declaration of Helsinki prior to drawing per-
ipheral blood for DNA extraction.
Homozygosity mapping and
sequencing
DNA samples of 11 patients were genotyped using the
Illumina HumanHap300-duo single nucleotide polymorphism
(SNP) microarrays (Illumina) containing over 318 000 SNPs.
Illumina Beadstudio v3.1.0 was used to call genotypes and all
samples had 499% call rate. Plink version 1.02 (Purcell et al.,
2007) was used to search for extended tracts of homozygosity
in each sample using a minimum length of 50 SNPs and 400
kb. The coding regions of the six positional candidate genes
(Supplementary Table 1) were Sanger sequenced from genomic
DNA using three patient samples (Patients a3, d3, and n4;
Supplementary Fig. 1). Primers are available upon request.
One patient (Patient a5; Supplementary Fig. 1) was whole-
exome sequenced. The sequencing protocol and sequence
data analysis are described in the Supplementary material.
Morpholino knockdown in zebrafish
embryos
The experimental work was carried out under protocols
approved by the Institutional Animal Care and Use
Committee, Duke University, following standard laboratory
procedures in accordance with the Duke Animal Care and
Use Program. We injected 1 nl (15 ng) of the translation-
blocking morpholino oligonucleotide (MO), znhit3_MO, into
wild-type zebraﬁsh embryos at the 1–2-cell stage and for the
rescue experiments 100 pg of relevant human mRNA. To
evaluate CNS integrity and oedema, injected embryos were
raised until 3 days post-fertilization (dpf); they were scored
for cardiac and/or generalized oedema and subsequently pro-
cessed for CNS analysis through whole-mount staining using
an antibody against acetylated tubulin (T7451, Sigma-Aldrich).
To evaluate differentiated granule cell expression in the cere-
bellum of 5 dpf developing zebraﬁsh larvae, we injected a
NeuroD:GFP reporter line (Drerup and Nechiporuk, 2013).
For more detailed methods, see Supplementary material.
Generation of CRISPR mutant
zebrafish embryos
For the CRISPR (clustered regularly-interspaced short palin-
dromic repeats) experiments, znhit3 guide RNA was generated
as described (Jao et al., 2013). The protocols for generation of
znhit3 guide RNA and F0 CRISPR mutant zebraﬁsh are
described in the Supplementary material. To generate the F1’
compound heterozygous or homozygous mutant znhit3 em-
bryos we intercrossed F0 adult founders. From each of the
produced clutches eight embryos were sacriﬁced, subjected to
T7 endonuclease I assay and Sanger sequenced to determine
the exact genotype and zygosity. Matings from two pairs
yielded 100% of the eight embryos tested with recessive
events and were subsequently phenotyped to assay the integrity
of the cerebellum as well as the head size (Fig. 3). The MO
and CRISPR phenotypic outcomes were qualitatively and
quantitatively concordant in their impact on cerebellar integ-
rity by counting the embryos with cerebellar abnormalities as
visualized by acetylated tubulin staining and measuring of the
area covered by NeuroD:GFP+ cells, respectively.
Expression plasmids and site-directed
mutagenesis
The cDNA clone of human ZNHIT3 was purchased from
imaGenes and cloned into pcDNA3.1 vector (Invitrogen) and
into the haemagglutinin (HA) tag containing pAHC expression
vector, a derivative of the pCIneo expression vector (Promega).
The c.92C4T nucleotide change was introduced into the wild-
type construct using the QuickChange Lightning Site-Directed
Mutagenesis Kit (Stratagene) and veriﬁed by sequencing.
Cell culture experiments, immuno-
blotting and immunocytochemistry
For measurement of protein stability, HeLa, COS-1 and BHK
cells (from ATCC) were cultured, transfected and exposed to
protein synthesis inhibitor cycloheximide or proteasome inhibi-
tor MG132 and analysed by immunoblotting as described in
detail in the Supplementary material. Cerebellar granule cell
cultures were prepared from postnatal Day 5 mice (C57BL)
and cultured for 2 days in vitro, as described previously
(Giulian and Baker, 1986; Lehtinen et al., 2009). HeLa,
BHK and mouse cerebellar granule cells were processed for
immunocytochemical confocal imaging analyses using Zeiss
LSM 700 or 780 microscope as described in detail in the
Supplementary material. Primary antibodies used were a
rabbit antibody to human ZNHIT3 (A301-214A, Bethyl
Laboratories; 1:200), a goat antibody to human lamin B1
(Santa Cruz Biotechnology; 1:1000) and a mouse antibody
to tubulin, beta III isoform (Chemicon; 1:200). Image process-
ing was done with ImageJ and Adobe Photoshop CS4
software.
Immunohistochemistry
Immunohistochemistry was done on sagittal parafﬁn sections
of embryonic Day 16.5, postnatal Day 3, and postnatal Day
10 or 21 mouse brain (see Supplementary material for details).
Primary antibodies used were a rabbit antibody to ZNHIT3
(A301-231A; Bethyl Laboratories, 1:600), a mouse antibody to
CDC47 (Thermo Scientiﬁc; 1:100), a mouse antibody to glial
ﬁbrillary acidic protein (GFAP) (M076101-2, Dako, Agilent
Technologies, 1:150) and a mouse antibody to calbindin
(Swant, 1:1000). The slides were analysed with Zeiss
Axioplan 2 epiﬂuorescence (Fig. 5A) or with Zeiss LSM 780
Confocal microscope (Fig. 5B) and with AxioVision 3.1 or
Zen 2010 software, respectively. Image processing was done
with ImageJ and Adobe Photoshop software.
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RNAi plasmid design
Mammalian hairpin (hp) RNA interference (RNAi) constructs
were designed as described (Gaudilliere et al., 2002).
The hpRNA targeting sequences are: GAAGAAGACAGAGT
GTCTCTG (Znhit3) and TACGCGCATAAGATTAGGGTA
(Scramble) (Christensen et al., 2011). Znhit3 rescue was gen-
erated by creating ﬁve silent base-pair mutations into the wild-
type cDNA encoding ZNHIT3 using the QuikChange Site-
Directed Mutagenesis Kit (Stratagene) as follows: GAGGAT
AGAGTCTCGCTC.
Survival assay
Cerebellar granule neurons prepared from postnatal Day 5
mouse cerebella were transfected with the hpRNA constructs
as described (Lehtinen et al., 2006). Brieﬂy, cultures were
transfected at postnatal Day 5 + 2 days in vitro (DIV) by
the calcium phosphate method. Seventy-two hours later, cells
were subjected to immunocytochemistry using an antibody to
green ﬂuorescent protein (GFP) (Abcam), and neuronal sur-
vival was assessed in a blinded manner in transfected GFP-
positive neurons based on the integrity of neuronal processes
and nuclear morphology (Hoechst) (Lehtinen et al., 2006).
Cerebellar slice cultures
Cerebella were harvested from postnatal Day 8 C57/Bl6 mouse
pups, immersed in plasmid DNA (2 mg/m) in complete Hanks
Balanced Salt Solution (HBSS), transferred to a CUY520-P5
Platinum block Petridish Electrode (Protech International),
and electroporated with an ECM 830 square wave electro-
porator (BTX Genetronics) at 80 V, ﬁve pulses, 50 ms pulse,
and 500 ms interval. Electroporated cerebella were embedded
in 3% low melting point agarose in HBSS, and 250 mm cor-
onal or sagittal cerebellar slices were prepared using a
VT1000S Vibratome (Leica Microsystems). Slices were trans-
ferred to Millicell

tissue culture inserts (Millipore) and cul-
tured in Eagle’s Basal Medium, with 1 mM L-glutamine, 0.5%
glucose, and ITS (Sigma) and 50 U/ml penicillin and strepto-
mycin and analysed at 48 or 72 h post-plating. The location of
GFP-positive staining cerebellar granule neurons was quanti-
ﬁed with respect to location of the Purkinje cell layer and
interpreted as migration as described (Yang et al., 2012).
Slices were imaged using BioGBS Zeiss 510 and analysed
using ImageJ and Amaxa softwares.
Statistical analyses
Zebraﬁsh embryos were analysed in a blinded manner. The
Pearson 2 test was used for cerebellar integrity and oedema
assays. In evaluating the area of the optic tectum and the area
covered by granule cells in NeuroD:GFP larvae, differences of
means by condition was calculated using a two-tailed Student’s
t-test. Statistical signiﬁcance was determined when P5 0.05.
For cerebellar granule cell survival 150 cells were counted
per treatment condition, per experiment, in a blinded manner
and analysed for statistical signiﬁcance by ANOVA followed
by Fisher’s Protected Least Signiﬁcant Difference post hoc test.
Statistical analyses represent a minimum of three separate ex-
periments with P50.05 considered as signiﬁcant. The
location of GFP-positive cerebellar granule neurons was ana-
lysed in a double-blind manner and quantiﬁed using unpaired
t-test.
Results
Identification of the ZNHIT3 gene
underlying PEHO syndrome
Homozygosity mapping in 11 Finnish patients with PEHO
syndrome (Supplementary Fig. 1) deﬁned a 433-kb region
on chromosome 17q12 (data not shown); none of 427
genotyped Finnish control individuals were homozygous.
Sanger sequencing of coding regions of the six positional
candidate genes in three patients (Patients a3, d3, and n3;
Supplementary Fig. 1) revealed a homozygous rare missense
variant, c.92C4T (p.Ser31Leu), in ZNHIT3 (MIM
604500; NM_004773.3), which encodes the zinc ﬁnger
HIT domain-containing protein 3 (ZNHIT3). Other genes
were excluded based on high population frequencies of the
identiﬁed variants (Supplementary Table 1). Whole-exome
sequencing in one patient with PEHO (Patient a5;
Supplementary material) identiﬁed the c.92C4T variant
as the only homozygous protein coding variant in the six
positional candidate genes (Supplementary Table 1).
Of the remaining 19 Finnish patients with clinically diag-
nosed PEHO syndrome, 18 were homozygous for
c.92C4T. The one patient with no mutations in
ZNHIT3 had progressive cerebellar atrophy, determined
by CT, and hypoplastic (as opposed to atrophic) optic
discs. Two of 40 Finnish patients with PEHO-like features
were homozygous for c.92C4T. One of these patients
lacked a history of infantile spasms and hypsarrhythmia,
though he otherwise fulﬁlled the clinical criteria. The
second patient initially had neuroimaging ﬁndings atypical
for PEHO syndrome, but these were later attributed to use
of vigabatrin, an anti-epileptic drug that inhibits break-
down of GABA (Walker and Ka¨lvia¨inen, 2011). None of
the 47 non-Finnish PEHO-like patients had mutations in
ZNHIT3.
The c.92C4T variant segregated in an autosomal reces-
sive manner in affected families. The carrier frequency in
the entire Exome Aggregation Consortium database was
0.07% (40/58 895 individuals) and 0.92% (31/3350)
among Finnish individuals, with no homozygous individ-
uals detected. The 155-amino acid ZNHIT3 polypeptide
(NP_004764.1) contains a N-terminal (amino acids 11–
42) cysteine-rich histidine triad motif -type zinc ﬁnger (zf-
HIT) domain (Fig. 2) found in nuclear proteins implicated
in transcription regulation and chromatin remodelling
(Iwahashi et al., 2002; He et al., 2007; Cuadrado et al.,
2010). It also contains a conserved LxxLL motif (Fig. 2A)
present in many nuclear receptor coregulators (Heery et al.,
1997). The p.Ser31Leu substitution affects a highly con-
served residue of the zf-HIT domain located next to one
of the zinc-coordinating cysteines (Fig. 2B), and based on
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three of four in silico predictions (Supplementary Table 1),
is deleterious. Collectively, these genetic data strongly sug-
gest that c.92C4T is the mutation causing PEHO
syndrome.
Knockdown and genome editing of
znhit3 in zebrafish
To get further biological causal evidence and to establish
the direction of effect of the p.Ser31Leu substitution, we
developed in vivo surrogate zebraﬁsh models. A BLASTp
query of the zebraﬁsh protein against the human proteome
identiﬁed the human ZNHIT3 as the major hit. RNA in
situ hybridization of the single znhit3 orthologue (66%
similarity; 49% identity) showed widespread expression
across the head of 5 dpf larvae (Supplementary Fig. 2).
Suppression of znhit3 by antisense morpholino injection
induced dosage-sensitive defects in a number of organs rele-
vant to human pathology. These included microcephaly
(through the surrogate measurement of the area of the
optic tectum) (Schulte et al., 2014; Borck et al., 2015)
and structural cerebellar defects (Fig. 3) as well as pericar-
diac oedema (Supplementary Fig. 3). These phenotypes
were speciﬁc. First, we were able to rescue all the above
pathologies by co-injecting embryos with wild-type human
ZNHIT3 capped mRNA (P = 0.002 for the optic tectum
Figure 1 Phenotypic features of PEHO syndrome. (A) Facial features of a patient at 1 year 2 months. Note the narrow forehead,
epicanthic folds, outward turning ear lobules, and open mouth. (B) The hands show oedema and the fingers are tapering. (C) Axial MRI at the age
of 5 months shows marked cerebellar atrophy. The supratentorial CSF spaces are normal. (D) At 5 months the myelination is almost normal for
the age (arrows). (E) At 1 year of age, cerebellar atrophy has progressed and is now severe and (F) myelination has proceeded only slightly and is
now markedly abnormal for the age (arrows). (G) In midline sagittal MRI at 1 year of age pons (arrowhead) is also atrophic, but not to the same
degree as the cerebellum (arrow). The supratentorial brain shows atrophy. (H) Atrophic cerebellar cortex from a PEHO patient (3 years 4
months). Haematoxylin and eosin-stained paraffin section showing an atrophic folium with clearly thinned molecular layer, almost total loss of
Purkinje cells, and prominent atrophy of the granule cell layer. The remaining Purkinje cells are pyknotic and disaligned (arrowhead). Original
magnification  100; Scale bar = 100 mm. Consent to publish facial images of the subject was obtained.
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assay, P50.0001 for the acetylated-tubulin-visualized
cerebellum integrity assay and P = 0.0003 for the oedema
assay; Fig. 3 and Supplementary Fig. 3). Second, CRISPR-
induced deletions in both F0 and F1’ 3 dpf zebraﬁsh em-
bryos (generated through an intercross among F0 znhit3
mutant founders) reproduced consistently the morphant
phenotypes in both qualitative and quantitative measures
(Fig. 3 and Supplementary Fig. 4).
Testing for rescue of microcephaly, cerebellar integrity
and pericardiac oedema showed, consistently, that
p.Ser31Leu mutant human mRNA yielded embryos indis-
tinguishable from morphants, suggesting that the
p.Ser31Leu represents a loss-of-function allele (P = 0.72
from MO and P5 0.0001 from MO + wild-type for the
optic tectum assay; P = 0.25 from MO and P = 0.0006
from MO + wild-type for the acetylated-tubulin-visualized
cerebellum integrity assay; and P = 1 from MO and
P = 0.0001 from MO + wild-type for the oedema assay;
Fig. 3 and Supplementary Fig. 3). Overexpression of either
the wild-type or p.Ser31Leu bearing human ZNHIT3
mRNA did not induce any signiﬁcant defects (Fig. 3 and
Supplementary Fig. 3).
To investigate the cerebellar phenotype we used zebraﬁsh
embryos expressing stably NeuroD:GFP, a marker for dif-
ferentiated granule cells. Both morphants and CRISPR mu-
tants had signiﬁcant cerebellar defects, with depletion of the
neuronal axons across the midline as well as the caudolat-
eral portion of the cerebellum (P5 0.0001 for both mor-
phant as well as F0 CRISPR mutant compared to control
larvae; Fig. 3 and Supplementary Fig. 5). This aberrant
granule cell phenotype could be rescued reproducibly by
co-injection of znhit3_MO with ZNHIT3 wild-type
(P50.0001) but not with mutant human mRNA
(P = 0.45; Supplementary Fig. 5).
Characterization of the ZNHIT3
protein
The effect of the p.Ser31Leu mutation on the putative tran-
scriptional co-regulatory function of ZNHIT3 (Iwahashi
et al., 2002; Koppen et al., 2009) was assessed in a series
of co-transfection-based reporter gene assays. Under condi-
tions in which TRAP220 (TR-associated protein 220)
(Yuan et al., 1998) clearly enhanced the activity of
thyroid hormone receptor-dependent transcription,
ZNHIT3 enhanced activity only slightly with no further
modulatory effect of p.Ser31Leu (Supplementary Fig. 6A
and B). In contrast, on HNF4-dependent transcription
(Supplementary Fig. 6C) and in a transcription repression
assay ZNHIT3 repressed transcription, and the p.Ser31Leu
substitution repressed transcription further (Supplementary
Fig. 6D). Using coimmunoprecipitation we showed that the
p.Ser31Leu mutation does not compromise the reported
interaction (Bizarro et al., 2014; Rothe et al., 2014) of
ZNHIT3 with NUFIP1 (Supplementary Fig. 7).
As immunoblotting of the coimmunoprecipitation and re-
porter gene assay samples repeatedly showed lower protein
levels for the p.Ser31Leu variant than wild-type ZNHIT3
(Supplementary Fig. 6C and D), we analysed their stability
in intact cells. First, inhibition of protein synthesis with
cycloheximide showed that endogenous ZNHIT3 in HeLa
cells is short-lived (half-life 52 h) (Fig. 4A). The cyclohex-
imide experiments of COS-1 cells (displaying low endogen-
ous level of ZNHIT3) transfected with ZNHIT3 expression
vectors demonstrated that the half-life of the p.Ser31Leu
mutant protein was approximately one-fourth of that of
wild-type (Fig. 4B). Blocking of the proteasome function
by MG132 abolished the difference between wild-type
and p.Ser31Leu protein (Fig. 4C), suggesting that the
Figure 2 The PEHO mutation affects a highly conserved amino acid in the functional domain of ZNHIT3. (A) A schematic picture
illustrating the secondary structure of the human ZNHIT3: beta strands, aa 19–21 and 28–31; alpha helix, aa 32–41; LxxLL, aa 101–105. The
arrow shows the location of Ser31. (B) Multiple alignment of zf-HIT domain of ZNHIT3. Asterisks and colons indicate fully conserved and highly
conserved residues, respectively. The residues coordinating zinc atoms are shown with red background and Ser31 with the yellow background.
1272 | BRAIN 2017: 140; 1267–1279 A.-K. Anttonen et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/140/5/1267/3059331 by Viikki Science Library, U
niversity of H
elsinki user on 12 August 2019
Figure 3 Knockdown and genome editing of znhit3 in zebrafish causes cerebellar defects and microcephaly. (A) Dorsal view of
the brains of 3 dpf zebrafish embryos stained with an antibody to acetylated tubulin. Control embryos and embryos injected with a znhit3
morpholino oligonucleotide (znhit3_MO), znhit3_MO with ZNHIT3 wild-type human mRNA (znhit3_MO +ZNHIT3_WT), znhit3_MO with
ZNHIT3 p.Ser31Leu mutant human mRNA (znhit3_MO +ZNHIT3_p.S31L) and F1’ embryos generated through an intercross of F0 znhit3 CRISPR
mutants (znhit3_ F1’_CRISPR) are shown. In the control brain, the area of the optic tectum (OT) is highlighted with a black dashed eclipse and the
area of the cerebellum (CB) with a white dashed rectangle. Enlarged images of the cerebellum are shown to the right of respective whole brain
images. In both the morphant embryos injected with znhit3_MO, and the F1’ CRISPR mutant embryos there is a reduction of the size of the optic
tectum, as well as marked degeneration of the axons forming the midline of the cerebellum, a finding that is consistent with cerebellar atrophy. In
the morphant model, both phenotypes were rescued by co-injection of znhit3_MO with ZNHIT3 wild-type human mRNA but not with ZNHIT3
p.Ser31Leu mutant human mRNA, suggesting that this variant represents a loss-of-function allele. (B) Quantification of the optic tectum area in
zebrafish larvae at 3 dpf (control n = 61, znhit3_MO n = 45, znhit3_MO +ZNHIT3_WT n = 44, znhit3_MO +ZNHIT3_p.S31L n = 42, ZNHIT3_WT
n = 37, ZNHIT3_p.S31L n = 53, znhit3_F1’_CRISPR n = 49). Error bars represent standard error of the mean (SEM). (C) Quantification of
embryos showing cerebellar defects (control n = 103, znhit3_MO n = 86, znhit3_MO +ZNHIT3_WT n = 94, znhit3_MO +ZNHIT3_p.S31L n = 85,
ZNHIT3_WT n = 93, ZNHIT3_p.S31L n = 109, znhit3_F1’_CRISPR n = 108). **P5 0.01; ***P5 0.001. WT = wild-type.
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lower steady-state level of the mutant is due to its more
rapid proteasomal degradation. Further, both endogenous
ZNHIT3 in HeLa cells (Fig. 4D) and wild-type ZNHIT3 in
BHK cells (Fig. 4E) displayed punctate staining both in
cytosol and nucleus. The p.Ser31Leu mutation did not
result in altered subcellular localization of ZNHIT3, but
the mutant protein was prone to form large nuclear aggre-
gates (Fig. 4E). Taken together, these data complement the
results from zebraﬁsh experiments and suggest that the
mechanism for the loss of function is impaired folding of
ZNHIT3 rendering it more prone than the wild-type pro-
tein to aggregation and degradation.
Neuronal expression of ZNHIT3
As the most striking neuropathology in PEHO syndrome is
observed in the cerebellum, characterized by remarkable
loss of granule cells and deformed Purkinje cells, and as
ﬁndings in zebraﬁsh embryos indicated granule cell defects,
we analysed the ZNHIT3 protein expression in mouse
cerebellum. The expression of ZNHIT3 was evident in pro-
liferating foetal granule cell precursors at embryonic Day
16.5, in proliferating and post-mitotic granule cells at post-
natal Days 3 and 10 (Fig. 5A) and was still visible, though
less prominent, in mature postnatal Day 21 cerebellum
(Fig. 5B). However, expression of ZNHIT3 in cerebellar
Purkinje cells was strong at postnatal Days 10 and 21.
Expression analysis of ZNHIT3 in Bergmann glia, which
is important for the migration of the cerebellar granule cells
(Rakic, 1971), remained inconclusive, since co-localization
of ZNHIT3 with the glial marker GFAP was only partial
(Fig. 5B and inset). In cultured postnatal cerebellar granule
cells the expression of ZNHIT3 was strong and mainly
nuclear (Fig. 5C), consistent with ﬁndings in cell lines.
Knockdown of Znhit3 by RNAi in
cerebellar granule cells
To investigate the impact of ZNHIT3 deﬁciency on cerebellar
pathology, we ﬁrst used a plasmid-based method of RNAi to
Figure 4 Compromised stability of p.Ser31Leu mutant ZNHIT3. (A) HeLa cells were exposed to cycloheximide (CHX), endogenous
ZNHIT3 was detected by immunoblotting and its half-life plotted. (B) Protein stability measurements in COS-1 cells ectopically expressing wild-
type (WT) ZNHIT3 or p.Ser31Leu mutant show that the substitution severely compromises the stability of ZNHIT3. (C) Effect of proteasome
inhibitor MG132 on ZNHIT3 levels in COS-1 cells. (D) Subcellular distribution of endogenous ZNHIT3 (green) in HeLa cells as assessed by
immunofluorescence staining and confocal microscopy. An antibody to lamin B1 (red) was used to label nuclear membranes. (E) BHK cells
transiently transfected with wild-type or p.Ser31Leu ZNHIT3 and treated with cycloheximide for 2.5 h. The cells were stained with an antibody to
ZNHIT3 (green) and with Hoechst (blue). Scale bars = 10 mm.
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Figure 5 Endogenous ZNHIT3 expression in the developing mouse cerebellum and cultured cerebellar granule cells.
(A) Developing cerebellar cortex at embryonic Day (E)16.5, postnatal Day (P)3 and P10 were stained with an antibody to ZNHIT3 (green). The
section at E16.5 was also stained with an antibody to CDC47 (red), a marker for mitotic cells. An arrowhead shows foetal precursor cells at
E16.5. Pictures were captured with an epifluorescence microscope. Scale bars = 50 mm. (B) Mouse cerebellar cortex at P10 and P21 stained with
an antibody to ZNHIT3 (green) and to calbindin or GFAP (red), markers for Purkinje and astroglial cells, respectively. Pictures are average
projections of stacks of four consecutive confocal microscope images. An insert shows a reconstructed orthogonal projection of the stack. Scale
bars = 50 mm. (C) Endogenous ZNHIT3 expression in cultured P5 mouse cerebellar granule cells. The cells were stained with antibodies to
ZNHIT3 (green) and tubulin, beta III isoform (red), a marker for neurons, and with Hoechst (blue). Scale bars = 20 mm.
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reduce the expression of mouse Znhit3 in 293T cells (Fig. 6A)
and in cultured primary mouse cerebellar granule neurons
(Fig. 6B). Knockdown of Znhit3 sensitized the neurons to
death, and the speciﬁcity of the effect was demonstrated by
co-expressing a ‘rescue’ form of Znhit3 (Zn-HIT3R) resistant
to Znhit3 RNAi (Fig. 6A and B). Further, knocking down
Znhit3 expression ex vivo in cerebella harvested from post-
natal Day 8 mouse pups resulted in reduced numbers of
ZNHIT3-deﬁcient cerebellar granule neurons located at
increased distances away from the external granule cell layer
(Fig. 6C). Reduced numbers of neurons were found within 50
mm, 100 mm, and 150 mm of the calbindin-positive Purkinje
cell layer compared to control (Fig. 6D and E). These data are
consistent with our observation of ectopic granule neurons in
cerebella of PEHO syndrome patients (Fig. 1H). Taken to-
gether, these data show that compromised neuronal survival
and impaired migration contribute to the cerebellar pathology
associated with defective ZNHIT3 function.
Discussion
Here we describe that loss-of-function of ZNHIT3, caused
by homozygosity for the p.Ser31Leu variant, underlies
autosomal recessive PEHO syndrome. The observed carrier
frequency (1%) of p.Ser31Leu in the Finnish population
is in line with the estimated incidence of PEHO syndrome
(Somer, 1993a). Deﬁnition of the clinical characteristics in
a molecularly uniform patient cohort (Table 1) conﬁrmed
the validity of the previously established clinical criteria
(Somer, 1993a) with the exception of infantile spasms
and hypsarrhythmia, which are not present in all PEHO
patients. We thus suggest that infantile spasms may be
removed as an essential clinical criterion for PEHO syn-
drome. The patients presented uniform neuroradiological
ﬁndings with progressive cerebellar atrophy and dysmyeli-
nation as essential diagnostic criteria. The clinical presenta-
tion among affected siblings was very similar.
Recently, ﬁve other genes have been implicated in pa-
tients with PEHO-like features (Gawlinski et al., 2016;
Langlois et al., 2016; Nahorski et al., 2016). A homozy-
gous frame-shift deletion in CCDC88A, which encodes an
actin binding protein, with an essential role in cellular mi-
gration and early development of mouse brain, was re-
ported in three consanguineous individuals (Nahorski
et al., 2016). However, the presence of microcephaly at
birth as well as polymicrogyria and pachygyria on MRI
Figure 6 ZNHIT3 deficiency leads to death and impaired
migration of mouse cerebellar granule neurons. (A) Left:
Lysates of 293T cells transfected with an expression vector
encoding haemagglutinin (HA) -tagged mouse ZNHIT3 (HA-Znhit3)
or control CMV plasmid together with the Znhit3 hpRNA (U6
Znhit3), control U6, or U6 Scramble plasmids, immunoblotted with
the antibodies to HA and AKT. Right: Lysates of 293T cells trans-
fected with mouse HA-Znhit3, Rescue HA-Znhit3 (R), or control
CMV plasmid together with the Znhit3 hpRNA or control U6
plasmid, immunoblotted (as in left). (B) Left: Percentage of cell death
of GFP-positive mouse cerebellar granule neurons transfected with
the Znhit3 hpRNA, control U6, or control Scramble plasmids to-
gether with the GFP expression plasmid after 72 h in culture, rep-
resented as mean  SEM (U6 control plasmid: 14.3  2.8; Znhit3
hpRNA: 38.7  4.7; Scramble: 19.4  3.1; **P5 0.01; n = 3). Right:
Neuronal death (as in left) of cells transfected with the Znhit3
hpRNA and wild-type HA-Znhit3, Rescue HA-Znhit3 (R), or control
CMV plasmids (HA-Znhit3 + Znhit3 hpRNA: 33.737  2.697;
Rescue HA-Znhit3 (R) + Znhit3 hpRNA: 14.15  3.282; CMV +
Znhit3 hpRNA: 28.553  1.86; *P5 0.05; **P5 0.01; n = 3). (C) Ex
vivo cerebellar slice cultures injected with control Scramble or
Znhit3 hpRNA and stained with antibodies to GFP (green) and cal-
bindin (magenta) showing fewer numbers of GFP-positive targeted
cells located past the calbindin-positive stained Purkinje cell layer in
Znhit3 injected compared to Scramble control. Scale bar = 40 mm.
(D) Quantification of GFP-positive targeted cells shown in C
Figure 6 Continued
located 150 mm past Purkinje cell layer (Znhit3 hpRNA: 57.0  3.0,
Scramble: 104.3  10.3; Mann-Whitney; *P5 0.05; n = 3). (E)
Quantification of GFP-positive targeted cell location shown in C.
Cell counts per fixed area (250 mm 100 mm) are shown at 50 mm
(Znhit3 hpRNA: 12.6  1.0, Scramble: 19  0.85) and at 100 mm
(Znhit3 hpRNA: 5.9  0.7, Scramble: 12.7  1.2; Mann-Whitney;
**P5 0.01; n = 3) past the calbindin-positive staining Purkinje cell
layer.
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argue against the diagnosis of PEHO syndrome in these
patients. A dominant de novo missense variant in the
motor domain of the KIF1A motor protein, involved in
the anterograde transport of synaptic-vesicle precursors
along axons (Riviere et al., 2011), was reported in one
patient (Langlois et al., 2016). Based on the MRI ﬁgure
in the paper, myelination in this patient seemed to be less
severely compromised than is typical for Finnish patients
with PEHO syndrome, suggesting that the patient does not
have PEHO syndrome. Indeed, in our cohort of Finnish
PEHO-like patients we have identiﬁed one patient with a
de novo KIF1A mutation (Lehesjoki, personal communica-
tion). Finally, identiﬁcation of de novo mutations both in
GNAO1 and in HESX1, and in CDKL5 in patients with
PEHO-like phenotypes led to the suggestion that PEHO
syndrome may represent a severe end of the spectrum of
the early-onset encephalopathies (Gawlinski et al., 2016).
Loss of znhit3 in zebraﬁsh caused defective cerebellar
development, which manifested as aberrant granule cells
and misaligned parallel ﬁbres in the cerebellar midline
and caudolateral cerebellar portion. These ﬁndings further
highlight the granule cells as the cerebellar cell type pre-
dominantly affected in ZNHIT3 deﬁciency. Since the ﬁrst
neuropathological evaluation of PEHO patients (Haltia and
Somer, 1993), it has been speculated that the almost total
loss of inner granule cell layer could be due to granule cell
death prior to or during migration (Somer, 1993b). Similar
defects in the migration and survival of granule cells were
further recapitulated through preliminary experiments in
the mouse and zebraﬁsh we report herein. To which
extent increased granule cell death and impaired migration
contribute to the phenotype remains to be explored
through additional in vivo studies. Towards this, the
generation of a stable mutant znhit3 line is necessary in
order to study the speciﬁc disease pathomechanisms, as
transient knockdown systems and mosaic F0 animals are
likely to display weaker phenotypes compared to null
models, as exempliﬁed by the phenotypic severity of the
F1’ animals compared to the milder effects of the MO
and the CRISPR editing. Nevertheless, the fact that all
three organisms, human, mouse and zebraﬁsh, display simi-
lar cellular and organismal defects at different evolutionary
stages, suggests a critical and conserved molecular function
for ZNHIT3 in cerebellum and establishes compromised
ZNHIT3 function as the causative determinant in PEHO
pathology.
ZNHIT3 (previously called TRIP3, TR interacting pro-
tein 3) was ﬁrst reported to interact with rat TR beta
(TRb1) in the presence of thyroid hormone (Lee et al.,
1995) and with retinoid X receptor (RXR) in a 9-cis-retin-
oic acid-responsive manner (Lee et al., 1995). However, the
functional consequences of these interactions were not
tested. Later, ZNHIT3 was reported to co-regulate the ac-
tivity of hepatocyte nuclear factor 4-alpha (HNF4)
(Iwahashi et al., 2002) and that of peroxisome prolifer-
ator-activated receptor gamma (PPAR) (Koppen et al.,
2009). Even though our in vitro reporter gene assays did
not conﬁrm the suggested transcriptional co-regulatory
function of ZNHIT3, it is possible that the effects of
mutated ZNHIT3 would be, at least in part, mediated
through perturbation in transcriptional regulation during
periods critical for cerebellar development. It is interesting
to note the similarity of the cerebellar changes between
PEHO syndrome patients (Haltia and Somer, 1993) and
thyroid hormone deﬁcient or thyroid hormone receptor
gene targeted rodents (Yuan et al., 1998; Hashimoto
Table 1 Occurrence of clinical features in PEHO patients with the p.Ser31Leu mutation in ZNHIT3
Main feature More detailed description n/na Percentage
Hypotonia Infantile, usually neonatal 26/26 100
Convulsive disorder 27/27 100
Infantile spasms with hypsarrhythmia 24/27 89
Age of onset, infantile spasms: 2–10 months 22/24
Initial seizure type other than infantile spasms 4/27 15
Profound motor and intellectual disability 27/27 100
Complete absence of speech 25/27 93
Absence or early loss of visual fixation 27/27 100
Atrophy of optic discs 19/24 79
ERG normal 18/18 100
VEP abnormal 18/21 86
Progressiveb brain atrophy 24/24 100
Predominantly cerebellum and brain stem 24/24 100
Dysmyelination on MRI 16/16 100
Oedema Limbs 21/28 75
Typical dysmorphic features 23/24 96
Brisk tendon reflexes At early stage; later, no reflexes 25/27 93
aIncludes three patients without confirmed mutation status in the patient sample, but detected heterozygous carrier status for p.Ser31Leu in parent samples.
bProgressive in patients with multiple CT/MRI scans.
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et al., 2001; Horn and Heuer, 2010; Portella et al., 2010;
Fauquier et al., 2011). A dominant-negative mutation in
the gene encoding the TR1 receptor has been shown to
primarily alter the differentiation of Purkinje cells and
Bergman glia leading to secondary impairment of migration
and terminal differentiation of granule cell precursors
(Fauquier et al., 2014). Our data on ZNHIT3 being ex-
pressed not only in Purkinje cells, but also in proliferating
and mature granule neurons imply that ZNHIT3 has spe-
ciﬁc functions also in granule neurons. Recent reports link-
ing ZNHIT3 to small nucleolar ribonucleoprotein particle
assembly and thus possibly to pre-ribosomal RNA process-
ing via its interaction with nuclear fragile X mental retard-
ation protein interacting protein 1 (NUFIP1) (Bardoni
et al., 2003; Rothe et al., 2014) imply that ZNHIT3 may
have roles beyond transcriptional regulation. However,
while we were able to conﬁrm the interaction of
ZNHIT3 with NUFIP1, the p.Ser31Leu substitution did
not inﬂuence this interaction.
The establishment of the nuclear functions of ZNHIT3
will be a next important step in understanding the patho-
mechanism of PEHO syndrome with focus on periods crit-
ical for proliferation, migration and maturation of
cerebellar granule cells. It will also be intriguing to ask
whether some of the genes known to phenocopy aspects
of the core PEHO pathology, might also be either regulated
by ZNHIT3 or partake in similar signalling cascades. At
present, ZNHIT3 is the only nuclear factor implicated in
this disorder. Identiﬁcation of the remaining PEHO-like
causing proteins and determining whether some/all of
these proteins are involved in the same core mechanisms
as ZNHIT3 thus has the possibility, not only to inform the
molecular aetiology of a broader group of disorders but
also to unravel key mechanisms required for normal cere-
bellar and cerebral development.
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